The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 530-537

  Süren, Dinç ^a   Yildirim, Mustafa ^b   Demirpençe, Özlem ^c   Kaya, Vildan ^d   Alikanoǧlu, Arsenal Sezgin ^a   Bülbüller, Nurullah ^a   Yildiz, Mustafa ^a   Sezer, Cem ^a  

^a Department of Pathology Antalya Education and Research Hospital ^*  (Turkey)

^b Ministry of Health Batman Regional Government Hospital   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

^d SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

Colorectal Neoplasms Pathology; HMGB1 Protein Diagnostic use; Prognosis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SPECIFIC SURVIVAL; COLLOID CARCINOMA; COLORECTAL CANCER; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; TUMOR GROWTH; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DEMOGRAPHY; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; STAINING AND LABELING;

EID: 84897393131     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.890531     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. Cancer J Clin, 2013; 63: 11-30
2. Eser S, Yakut C, Özdemir R et al: Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev, 2010; 11: 1731-39
3. Edge SB, Byrd DR, Compton CC et al: Editors: AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed. New York: Springer; 2010
4. Kim GP, Colangelo LH, Wieand HS et al: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol, 2007; 25: 767-72
5. Han DP, Zhu QL, Cui JT et al: Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit, 2012; 18(6): BR237-46
6. Gao L, Bai L, Nan Qz: Activation of Rho GTPase Cdc42 promotes adhesion and invasion in colorectal cancer cells. Med Sci Monit Basic Res, 2013; 19: 201-7
7. Zhang J, McCauley MJ, Maher LJ III et al: Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res, 2009;37: 1107-14
8. Kostova N, Zlateva S, Ugrinova I, Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem, 2010; 337: 251-58
9. Sharma A, Ray R, Rajeswari MR: Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest, 2008; 26: 843-51
10. Gnanasekar M, Thirugnanam S, Ramaswamy K: Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol, 2009; 34: 425-31
11. Yao X, Zhao G, Yang H et al: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol, 2010; 136: 677-84
12. Rhodes DR, Yu J, Shanker K: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA, 2004; 101: 9309-14
13. Court EL, Ann Smith M, Avent ND et al: DNA microarray screening of differential gene expression in bone marrow samples from AML, non-AML patients and AML cell lines. Leuk Res, 2004; 28: 743-53
14. Soumaoro LT, Uetake H, Higuchi T et al: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res, 2004; 10: 8465-71
15. Masunaga R, Kohno H, Dhar DK et al: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res, 2000; 6: 4064-68
16. Shen X, Hong L, Sun H et al: The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep, 2009; 22: 535-39
17. Liu F, Zhang Y, Peng Z et al: High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med, 2012; 10: 135
18. Chuangui C, Peng T, Zhentao Y: The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res, 2012; 18: 1021-27
19. Chen J, Xi B, Zhao Y et al: High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol, 2012; 126: 109-17
20. Liu Y, Xie C, Zhang X et al: Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer, 2010; 46: 3007-15
21. Hao Q, Du XQ, Fu X, Tian J: Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi, 2008; 30: 292-95
22. Alexandrova EA, Beltchev BG: Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem Biophys Res Commun, 1988; 154: 918-27
23. Kang HJ, Lee H, Choi HJ et al: Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest, 2009; 89: 948-59
24. Jantzen HM, Admon A, Bell SP, Tjian R: Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature, 1990; 344: 830-36
25. Topalova D, Ugrinova I, Pashev IG, Pasheva EA: HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int J Biochem Cell Biol, 2008; 40: 1536-42
26. Livesey KM, Tang D, Zeh HJ, Lotze MT: Not just nuclear proteins: 'novel' autophagy cancer treatment targets-p53 and HMGB1. Curr Opin Investig Drugs, 2008; 9: 1259-63
27. Jiao Y, Wang HC, Fan SJ: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin, 2007; 28: 1957-67
28. Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapyinduced DNA damage. Mol Cancer Ther, 2009; 8: 864-72
29. Ito N, DeMarco RA, Mailliard RB et al: Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol, 2007; 81: 75-83
30. Campana L, Bosurgi L, Rovere-Querini P: HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol, 2008; 20: 518-23
31. Völp K, Brezniceanu ML, Bösser S et al: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut, 2006; 55: 234-42
32. Brezniceanu ML, Völp K, Bösser S et al: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J, 2003; 17: 1295-97
33. Schlueter C, Weber H, Meyer B et al: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol, 2005; 166: 1259-63
34. Sitohy B, Nagy J, Dvorak H: Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res, 2012; 72: 1909-14
35. Wang W, Jiang H, Zhu H et al: Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett, 2013; 5: 884-88
36. Ellerman JE, Brown CK, de Vera M et al: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res, 2007; 13: 2836-48
37. Liang X, Chavez AR, Schapiro NE et al: Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol, 2009; 86: 599-607
38. Lim SC, Choi JE, Kim CH et al: Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med, 2007; 20: 187-92
39. Dong Xda E, Ito N, Lotze MT et al: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother, 2007; 30: 596-606
40. Dias AS, Porawski M, Alonso M et al: Quercetin decreases oxidative stress, NF-kappaB activation, and iNOS overexpression in liver of streptozotocininduced diabetic rats. J Nutr, 2005; 135: 2299-304
41. Tang D, Kang R, Xiao W et al: Quercetin Prevents Lipopolysaccharide-induced HMGB1 Release and Proinflammatory Function. Am J Respir Cell Mol Biol, 2009; 41: 651-60
42. Lamson DW, Brignall MS: Antioxidants and cancer, part 3: quercetin. Altern Med Rev, 2000; 5: 196-208
43. Li ZJ, Song B, Liu J et al: Inhibitory effect of silencing of HMGB1 gene expression on the invasive and metastatic abilities of MGC-803 gastric cancer cells. Zhonghua Zhong Liu Za Zhi, 2013; 35: 244-48
44. Moriwaka Y, Luo Y, Ohmori H et al: HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology, 2010; 77: 17-23
45. Kuniyasu H, Yano S, Sasaki T et al: Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol, 2005; 166: 751-60
46. Peng RQ, Wu XJ, Ding Y et al: Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer, 2010; 16: 496
47. Kusume A, Sasahira T, Luo Y et al: Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology, 2009; 76: 155-62
48. Fahmueller YN, Nagel D, Hoffmann RT et al: Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer, 2013; 15: 2349-58
49. Tang D, Kang R, Zeh HJ III, Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta, 2010; 1799: 131-40